期刊文献+

凝血酶激活的纤溶抑制物与血栓性疾病 被引量:1

Thrombin Activatabie Fibrinolysis Inhibitor and Thrombotic Disease
下载PDF
导出
摘要 目前,血栓性疾病严重威胁着患者的生命与健康,用特异性溶栓药物进行治疗是防治血栓性疾病的重要措施,为此人们仍不断探索新的治疗方法。凝血酶激活的纤溶抑制物(thrombin activatabie fibrinolysis inhibitor,TAFI)是近年来发现存在于血浆中的一种蛋白酶原,是体内纤溶系统的重要成分,它被激活后具有抑制纤维蛋白溶解的作用。由于它与血栓性疾病的发生发展有关,已成为医学界研究如何防治血栓性疾病的热点之一,其作用日益受到重视。
作者 杨萍 王颖
机构地区 天津市环湖医院
出处 《血栓与止血学》 2006年第5期231-233,共3页 Chinese Journal of Thrombosis and Hemostasis
  • 相关文献

参考文献17

  • 1[1]BAJZAR L.Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway[J].Arterioscler Thrombo Vasc Biol,2000,20(12):2511-2518.
  • 2[2]CHETAILLE P,ALESSI MC,KOUASSI D,et al.Plasma TAFI antigen variations in healthy subjects[J].Thromb Haemost,2000,83:902-905.
  • 3[3]ZHAO L,MORSER J,BAJZAR L,et al.Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms[J].Thromb Haemost,1998,80(6):949-955.
  • 4张子彦.凝血酶激活的纤溶抑制物的研究进展[J].国外医学(输血及血液学分册),2002,25(5):390-392. 被引量:2
  • 5[5]SAKHAROV DV,PLOW EF,RIJKEN DC,et al.On the mechanism of the antifibrinolytic activity of biological[J].Chemistry,1997,272(22):1447.
  • 6[6]MOSNIER LO,MEIJER JC,BOUMA BN.Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin[J].Thromb Haemost,2001,85 (1):5-11.
  • 7[7]MOSNIER LO,Von dem BORNE PAK,Meijers JCM,et,al..Plasma TAFI level influence the clotlysis time in health individuals in the presence of an intact intrinsic pathway of coagulation[J].Thromb Haemost,1998,80:829-835.
  • 8[8]CHETAILLE P,ALESSI MC,KOUASSI D,et ai.Plasma TAFI antigen variations in health subjects[J].Thromb Haemost,2000,83(6):902-905.
  • 9[9]SCHNEIDER M,BOFFA M,STEWART R,et al.Two naturally occurring of TAFI (Thr 325 and Ile 325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme[J].The Joumal of Biological Chemistry,2001,227(2):1021.
  • 10[10]KLEMENT P,LIAO P,BAJZAR L,Anovel approech to arterial thrombolysis[J].Blood,1999,94 (8):2735-2743.

二级参考文献30

  • 1[1]Chetaille P,Alessi MC,Kouassi D,et al. Plasma TAFI Antigen Variations in Healthy Subjects [J]. Thromb Haemost,2000; 83: 902~ 905.
  • 2[2]Zhao L,Morser J,Bajzar L,et al. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms[J]. Thromb Haemost,1998;80(6) :949~955.
  • 3[3]Mosnier LO,Von der Borne PAK,Meijers JCM,et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation [J]. Thromb Haemost, 1998; 80: 829~ 835.
  • 4[4]Schneider M,Boffa M,Stewart R,Rahman ML,Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr 325 and Ile 325)differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme [J]. J Biol Chem, 2002 ; 277: 9944~ 9951.
  • 5Bajzar L,Manuel R,Nesheim ME,et al .J Biol Chem,1995,270:14477
  • 6Henry M,Aubert H,Morange PE,et al.Blood,2001,97:2053
  • 7Brouwers GT, Vos HL, Leebeek FWG, et al. Blood, 2001,98:1992
  • 8Mosiner LO,von dem Borne PAK, et al. Thromb Haemost, 1998,80: 829
  • 9Chetalille P, Alessi MC, Kouassi D, et al. Thromb Haemost, 2000,83: 829
  • 10Chabloz P,Reber T,Blehlen F,et al. Br J Haematol,2001,115:150

共引文献12

同被引文献8

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部